Cargando…
Digital health technology derived measures: Biomarkers or clinical outcome assessments?
Digital health technologies (DHTs) present unique opportunities for clinical evidence generation but pose certain challenges. These challenges stem, in part, from existing definitions of drug development tools, which were not created with DHT‐derived measures in mind. DHT‐derived measures can be lev...
Autores principales: | Izmailova, Elena S., Demanuele, Charmaine, McCarthy, Marie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339690/ https://www.ncbi.nlm.nih.gov/pubmed/37118983 http://dx.doi.org/10.1111/cts.13529 |
Ejemplares similares
-
Considerations for Conducting Bring Your Own “Device” (BYOD) Clinical Studies
por: Demanuele, Charmaine, et al.
Publicado: (2022) -
Empowering drug development: Leveraging insights from imaging technologies to enable the advancement of digital health technologies
por: Izmailova, Elena S., et al.
Publicado: (2022) -
Development of digital biomarkers for resting tremor and bradykinesia using a wrist-worn wearable device
por: Mahadevan, Nikhil, et al.
Publicado: (2020) -
Digital technologies: Innovations that transform the face of drug development
por: Izmailova, Elena S., et al.
Publicado: (2023) -
Digital biomarkers: Convergence of digital health technologies and biomarkers
por: Vasudevan, Srikanth, et al.
Publicado: (2022)